quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:33:42·34d
SECFiling
TG Therapeutics Inc. logo

TG Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

TGTX· TG Therapeutics Inc.
Health Care
Original source

Companies

  • TGTX
    TG Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Oct 6UpdateH.C. Wainwright$60.00
  • Jul 10UpdateGoldman$37.00
  • Oct 29UpdateTD Cowen$50.00
  • Aug 2UpdateGoldman$12.00
  • Jun 26UpdateJefferies$40.00
  • May 20UpdateBofA Securities$5.00

Related

  • PR1d
    TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
  • PR8d
    TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by TG Therapeutics Inc.
  • PR35d
    TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
  • PR48d
    TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
  • PR52d
    Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
  • SEC55d
    SEC Form 10-K filed by TG Therapeutics Inc.
  • SEC56d
    TG Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022